The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis
Abstract
Objective: MicroRNAs (miRNAs) are single‐stranded, small noncoding RNAs that regulate gene expression. Because they are stable in serum, they are being developed as biomarkers for cancer and other diseases. In multiple sclerosis (MS), miRNAs have been studied in cell populations but not in the circulation. In MS, a major challenge is to develop immune biomarkers to monitor disease. We asked whether circulating miRNAs could be identified in MS and whether they are linked to disease stage and/or disability. Methods: A total of 368 miRNAs were measured in ethylenediaminetetraacetic acid plasma in 10 relapsing–remitting MS (RRMS) patients, 9 secondary progressive MS (SPMS) patients, and 9 healthy controls (HCs) using miRCURY LNA™ Universal RT microRNA polymerase chain reaction panels. Nineteen miRNAs from this discovery set were validated using qPCR on an independent set of 50 RRMS patients, 51 SPMS patients, and 32 HCs. Results: We found that circulating miRNAs are differentially expressed in RRMS and SPMS versus HCs and in RRMS versus SPMS. We also found miRNAs to be linked to Expanded Disability Status Scale (EDSS). hsa‐miR‐92a‐1* was identified in the largest number of comparisons. It was different in RRMS versus SPMS, and RRMS versus HCs, and showed an association with EDSS and disease duration. miR‐92 has target genes involved in cell cycle regulation and cell signaling. The let‐7 family of miRNAs differentiated SPMS from HCs and RRMS from SPMS. let‐7 miRNAs regulate stem cell differentiation and T cell activation, activate Toll‐like receptor 7, and are linked to neurodegeneration. hsa‐miR‐454 differentiated RRMS from SPMS, and hsa‐miR‐145 differentiated RRMS from HCs and RRMS from SPMS. Interestingly, the same circulating miRNAs (let‐7 and miR‐92) that were differentially expressed in RRMS versus SPMS also differentiated amyotrophic lateral sclerosis (ALS) from RRMS subjects, but were not different between SPMS and ALS, suggesting that similar processes may occur in SPMS and ALS. Interpretation: Our results establish circulating miRNAs as a readily accessible blood biomarker to monitor disease in MS. ANN NEUROL 2013;73:729–740
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Hosmer, D. W., & Lemeshow, S. (2000) · doi:10.1002/0471722146 · Cited by 20,302
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Non-coding RNAs in human disease
Esteller, M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3074 · Cited by 4,825
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems
Bustin, S. (2002) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0290023 · Cited by 2,546
Roush, S., & Slack, F. J. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.07.007 · Cited by 1,328
Xiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., Henderson, J. M., Kutok, J. L., & Rajewsky, K. (2008) · Nature Immunology · doi:10.1038/ni1575 · Cited by 1,228
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Kasinski, A. L., & Slack, F. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3166 · Cited by 936
Cited by
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Self-citationMyasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms
Berrih-Aknin, S., & Le Panse, R. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.12.011 · Cited by 383
Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers
Hamam, R., Hamam, D., Alsaleh, K. A., Kassem, M., Zaher, W., Alfayez, M., Aldahmash, A., & Alajez, N. M. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.440 · Cited by 322
Baumann, V., & Winkler, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.116 · Cited by 297
Non-coding RNA: a new frontier in regulatory biology
Fu, X.-D. (2014) · National Science Review · doi:10.1093/nsr/nwu008 · Cited by 259
Metadata
- Authors
- Gandhi, R., Healy, B., Gholipour, T., Egorova, S., Musallam, A., Hussain, M. S., Nejad, P., Patel, B., Hei, H., Khoury, S., Quintana, F., Kivisakk, P., Chitnis, T., & Weiner, H. L.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2013-06
- Volume
- 73
- Issue
- 6
- Pages
- 729-740
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1588752417
- Cited by
- 258
- References
- 58
- FWCI
- 20.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. https://app.cochat.ai/papers/10.1002/ana.23880
- The paper
- Gandhi, R., Healy, B., Gholipour, T., Egorova, S., Musallam, A., Hussain, M. S., Nejad, P., Patel, B., Hei, H., Khoury, S., Quintana, F., Kivisakk, P., Chitnis, T., & Weiner, H. L. (2013). Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. Annals of Neurology. https://doi.org/10.1002/ana.23880
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.